dipyridamole has been researched along with Hyperlipidemias in 14 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (78.57) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, RJ | 1 |
| Albers, G | 1 |
| Alberts, MJ | 1 |
| Benavente, O | 1 |
| Furie, K | 1 |
| Goldstein, LB | 1 |
| Gorelick, P | 1 |
| Halperin, J | 1 |
| Harbaugh, R | 1 |
| Johnston, SC | 1 |
| Katzan, I | 1 |
| Kelly-Hayes, M | 1 |
| Kenton, EJ | 1 |
| Marks, M | 1 |
| Sacco, RL | 1 |
| Schwamm, LH | 1 |
| Bollinger, A | 1 |
| Biland, L | 1 |
| Brunner, U | 1 |
| Kappert, A | 1 |
| Krähenbühl, B | 1 |
| Mahler, F | 1 |
| Monti, M | 1 |
| Nachbur, B | 1 |
| Schneider, E | 1 |
| Widmer, LK | 1 |
| Pyrig, LA | 1 |
| Petrun, NM | 1 |
| Nikulina, GG | 1 |
| Gorelova, NR | 1 |
| Bonchek, LI | 1 |
| Boerboom, LE | 1 |
| Olinger, GN | 1 |
| Pepper, JR | 1 |
| Munns, J | 1 |
| Hutchinson, L | 1 |
| Kissebah, AH | 1 |
| Paredero Del Bosque Martin, V | 1 |
| Yamada, M | 1 |
| Omata, K | 1 |
| Abe, F | 1 |
| Ito, S | 1 |
| Abe, K | 1 |
| Bigi, R | 1 |
| Desideri, A | 1 |
| Cortigiani, L | 1 |
| Bax, JJ | 1 |
| Celegon, L | 1 |
| Fiorentini, C | 1 |
| Mustard, JF | 1 |
| Packham, MA | 1 |
| Kinlough-Rathbone, RL | 1 |
| Zannino, L | 1 |
| Salvadori, G | 1 |
| Strano, A | 1 |
| Novo, S | 1 |
| O'Sullivan, DJ | 1 |
| Lim, GH | 1 |
| Darveniza, P | 1 |
| Coffey, GL | 1 |
| Hammerl, H | 1 |
| Nebosis, G | 1 |
| Pichler, O | 1 |
| Studlar, M | 1 |
| Goto, Y | 1 |
| Nishino, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
3 reviews available for dipyridamole and Hyperlipidemias
| Article | Year |
|---|---|
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
[Platelet aggregation inhibitors. Their possible use in pediatric pathology].
Topics: Age Factors; Anti-Inflammatory Agents; Aspirin; Child; Clofibrate; Dextrans; Diabetes Mellitus, Type | 1979 |
[Prospects of antiaggregant therapy in prevention of atherosclerosis].
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Arteriosclerosis; Aspirin; Blood Coagulation Diso | 1979 |
11 other studies available for dipyridamole and Hyperlipidemias
| Article | Year |
|---|---|
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru | 2008 |
[Therapy of peripheral arterial occlusive diseases. Round table conference].
Topics: Alprostadil; Angioplasty, Balloon; Anti-Bacterial Agents; Anticoagulants; Arterial Occlusive Disease | 1983 |
Abnormalities of lipid metabolism and methods of their correction in patients with glomerulonephritis.
Topics: Adolescent; Adult; Arteriosclerosis; Clofibrate; Dipyridamole; Female; Glomerulonephritis; Humans; H | 1984 |
Prevention of lipid accumulation in experimental vein bypass grafts by antiplatelet therapy.
Topics: Animals; Arteriosclerosis; Aspirin; Coronary Artery Bypass; Dipyridamole; Hyperlipidemias; Lipid Met | 1982 |
[Indications for surgical treatment and medical treatment of atherosclerosis].
Topics: Arteriosclerosis; Aspirin; Cholestyramine Resin; Clofibrate; Dextrothyroxine; Dipyridamole; Humans; | 1980 |
Changes in prostacyclin, thromboxane A2 and F2-isoprostanes, and influence of eicosapentaenoic acid and antiplatelet agents in patients with hypertension and hyperlipidemia.
Topics: Aspirin; Dinoprost; Dipyridamole; Eicosapentaenoic Acid; Epoprostenol; Humans; Hyperlipidemias; Hype | 1999 |
Stress echocardiography for risk stratification of diabetic patients with known or suspected coronary artery disease.
Topics: Adrenergic beta-Agonists; Age Factors; Aged; Coronary Disease; Diabetes Complications; Diabetes Mell | 2001 |
Multiple progressive intracranial arterial occlusions ('moyamoya' disease).
Topics: Adrenal Cortex Hormones; Adult; Antihypertensive Agents; Arterial Occlusive Diseases; Cerebral Angio | 1977 |
[Influence of a combined treatment using clofibrate and persantin persantinat on increased serum lipid levels].
Topics: Adult; Cholesterol; Clofibrate; Dipyridamole; Drug Synergism; Humans; Hyperlipidemias; Male; Middle | 1973 |
[Arteriosclerosis].
Topics: Adult; Aged; Arteriosclerosis; Cholestyramine Resin; Diet Therapy; Dipyridamole; Humans; Hyperlipide | 1971 |
[Studies on platelet adhesiveness. II. On various diseases].
Topics: Adenosine; Arteriosclerosis; Dextrans; Diabetes Mellitus; Dipyridamole; Female; Fibrinolytic Agents; | 1970 |